252 related articles for article (PubMed ID: 2771068)
21. Magnetic resonance imaging of intracranial tumors using gadolinium-DTPA. Initial experience with fast imaging.
Niendorf HP; Felix R; Laniado M; Schörner W; Kornmesser W; Claussen C
Acta Radiol Suppl; 1986; 369():561-3. PubMed ID: 2980558
[TBL] [Abstract][Full Text] [Related]
22. T1 and T2 relaxation times on gadolinium-diethylenetriaminepentaacetic acid enhanced magnetic resonance images of brain tumors.
Yamada S; Kubota R; Yamada K; Ono S; Hishinuma T; Matsuzawa T; Fujiwara S
Tohoku J Exp Med; 1990 Feb; 160(2):145-8. PubMed ID: 2353348
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.
Fan B; Li M; Wang X; Xu Y; Li F; Zhang L; Jiang J; Jiang Y
J Magn Reson Imaging; 2017 Jun; 45(6):1827-1834. PubMed ID: 27696616
[TBL] [Abstract][Full Text] [Related]
24. [The use of hyperventilation for improving the visualization of glial tumors of the brain in magnetic resonance tomography using the contrast substance Gd-DTPA].
Pronin IN; Kornienko VN; Petriaĭkin AV; Golanov AV
Zh Vopr Neirokhir Im N N Burdenko; 1995; (3):10-3. PubMed ID: 7483947
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of Gd-DTPA-enhanced MR imaging of benign extraaxial tumors.
Haughton VM; Rimm AA; Czervionke LF; Breger RK; Fisher ME; Papke RA; Hendrix LE; Strother CM; Turski PA; Williams AL
Radiology; 1988 Mar; 166(3):829-33. PubMed ID: 3340779
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of gadobenate dimeglumine vs gadopentetate dimeglumine in contrast- enhanced magnetic resonance imaging for diagnosis of solitary brain metastases].
Wang QJ; Wang Y; Xu X; Xiao H; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1968-73. PubMed ID: 22200693
[TBL] [Abstract][Full Text] [Related]
27. Contrast-enhanced magnetic resonance imaging of the abdomen and pelvis.
Hamm B; Laniado M; Saini S
Magn Reson Q; 1990 Apr; 6(2):108-35. PubMed ID: 2202422
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging of human cerebral infarction: enhancement with Gd-DTPA.
Imakita S; Nishimura T; Naito H; Yamada N; Yamamoto K; Takamiya M; Yamada Y; Sakashita Y; Minamikawa J; Kikuchi H
Neuroradiology; 1987; 29(5):422-9. PubMed ID: 3454165
[TBL] [Abstract][Full Text] [Related]
29. Magnetic resonance imaging of acoustic neuromas: the role of gadolinium-DTPA.
Stack JP; Ramsden RT; Antoun NM; Lye RH; Isherwood I; Jenkins JP
Br J Radiol; 1988 Sep; 61(729):800-5. PubMed ID: 3179642
[TBL] [Abstract][Full Text] [Related]
30. Gd DTPA: a review of clinical indications in central nervous system magnetic resonance imaging.
Runge VM; Carollo BR; Wolf CR; Nelson KL; Gelblum DY
Radiographics; 1989 Sep; 9(5):929-58. PubMed ID: 2678298
[TBL] [Abstract][Full Text] [Related]
31. Recurrent medulloblastoma: frequency of tumor enhancement on Gd-DTPA MR imaging.
Rollins N; Mendelsohn D; Mulne A; Barton R; Diehl J; Reyes N; Sklar F
AJR Am J Roentgenol; 1990 Jul; 155(1):153-7. PubMed ID: 2112838
[TBL] [Abstract][Full Text] [Related]
32. Spin echo and inversion recovery sequences for gadolinium-DTPA enhanced magnetic resonance imaging of intracranial tumors.
Laniado M; Niendorf HP; Schörner W; Felix R
Acta Radiol Suppl; 1986; 369():469-71. PubMed ID: 2980530
[TBL] [Abstract][Full Text] [Related]
33. Correlation between Gd-enhanced MR imaging and histopathology in treated and untreated 9L rat brain tumors.
Wilkins DE; Raaphorst GP; Saunders JK; Sutherland GR; Smith IC
Magn Reson Imaging; 1995; 13(1):89-96. PubMed ID: 7898284
[TBL] [Abstract][Full Text] [Related]
34. Brain metastasis of small cell lung carcinoma: comparison of Gd-DTPA enhanced magnetic resonance imaging and enhanced computerized tomography.
Nomoto Y; Miyamoto T; Yamaguchi Y
Jpn J Clin Oncol; 1994 Oct; 24(5):258-62. PubMed ID: 7967105
[TBL] [Abstract][Full Text] [Related]
35. Gd-DTPA: an i.v. contrast agent for clinical MRI.
Runge VM
Int J Rad Appl Instrum B; 1988; 15(1):37-44. PubMed ID: 3280522
[No Abstract] [Full Text] [Related]
36. [Changes in tissue T1 of brain tumor following GD-DTPA administration--differences in T1 time course and tissue-blood ratio by histological types].
Yoshida K; Furuse M; Kaneoke Y; Sasou K; Motegi Y
No To Shinkei; 1988 Jun; 40(6):531-7. PubMed ID: 3224029
[TBL] [Abstract][Full Text] [Related]
37. [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia.
Davis WK; Boyko OB; Hoffman JM; Hanson MW; Schold SC; Burger PC; Friedman AH; Coleman RE
AJNR Am J Neuroradiol; 1993; 14(3):515-23. PubMed ID: 8517334
[TBL] [Abstract][Full Text] [Related]
38. Malignancy and viability of intraparenchymal brain tumours: correlation between Gd-DTPA contrast MR images and proliferative potentials.
Yoshii Y; Komatsu Y; Yamada T; Hyodo A; Nose T; Kobayashi E
Acta Neurochir (Wien); 1992; 117(3-4):187-94. PubMed ID: 1414520
[TBL] [Abstract][Full Text] [Related]
39. Gadolinium-DTPA in magnetic resonance imaging of the brain.
Valk J; De Slegte RG; Crezee FC; Hazenberg GJ; Thjaha SI
Neurosurg Rev; 1987; 10(2):87-92. PubMed ID: 3448513
[TBL] [Abstract][Full Text] [Related]
40. Gd-DTPA as a contrast agent in CT.
Bloem JL; Wondergem J
Radiology; 1989 May; 171(2):578-9. PubMed ID: 2704827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
